Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia

Current Opinion in Oncology

Volumn 23, Issue 2, 2011, Pages 197-202

  Horwitz, Mitchell E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

conditioning regimen; leukemia; myelodysplastic syndrome; nonmyeloablative; reduced intensity; stem cell transplantation

Indexed keywords

ALEMTUZUMAB; BUSULFAN; FLUDARABINE; MELPHALAN; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ADULT STEM CELL; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; HUMAN; INTERMETHOD COMPARISON; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; TREATMENT OUTCOME; WHOLE BODY RADIATION;

HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; STEM CELL TRANSPLANTATION;

EID: 79952007811     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328342b82a     Document Type: Article

References (28)

1. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91:756-763. (Pubitemid 28078275)
2. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graftversus- leukemia without myeloablative therapy. Blood 1997; 89:4531-4536. (Pubitemid 27260263)
3. Valcarcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versushost disease is the strongest factor improving survival. J Clin Oncol 2008; 26:577-584. (Pubitemid 351264351)
4. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24:444-453. (Pubitemid 46630463)
5. Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15:367-369.
6. Ringden O, Labopin M, Ehninger G, et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27:4570-4577.
7. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than .50. years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19:2304-2312. (Pubitemid 41748028)
8. Marks DI, Wang T, Perez WS, et al. The outcome of full-intensity and reducedintensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood 2010; 116:366-374.
9. Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2010; 116:4439-4443.
10. Luger S, Ringden O, Perez WS, et al. Similar outcomes using myeloablative versus reduced intensity and non-myeloablative allogeneic transplant preparative regimens for AML or MDS: from the Center for International Blood and Marrow Transplant Research. ASH Annual Meeting Abstracts 2008; 112:348.
11. Luger S, Ringden O, Perez W, et al. Similar outcomes using myeloablative versus reduced intensity and non-myeloablative allogeneic transplant preparative regimens for AML or MDS: from the Center for International Blood and Marrow Transplant Research. Blood 2008; 112:348.
12. Martino R, Valcarcel D, Brunet S, et al. Comparable nonrelapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission. Bone Marrow Transplant 2008; 41:33-38.
13. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105:1810-1814. (Pubitemid 40223707)
14. Shimoni A, Hardan I, Shem-Tov N, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006; 20:322-328. (Pubitemid 43148672)
15. Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20:128-135.
16. Rodriguez R, Nademanee A, Ruel N, et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12:1326-1334. (Pubitemid 44858267)
17. Warlick ED, Cioc A, Defor T, et al. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant 2009; 15:30-38.
18. Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25:4246-4254. (Pubitemid 47554249)
19. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111:1827-1833. (Pubitemid 351451489)
20. Marks DI, Perez WS, He W, et al. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood 2008; 112:426-434.
21. Jimenez M, Martinez C, Ercilla G, et al. Reduced-intensity conditioning regimen preserves thymic function in the early period after hematopoietic stem cell transplantation. Exp Hematol 2005; 33:1240-1248. (Pubitemid 41416973)
22. Satwani P, Baldinger L, Freedman J, et al. Incidence of viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2009; 15:1587-1595.
23. Bachanova V, Brunstein CG, Burns LJ, et al. Fewer infections and lower infection-related mortality following nonmyeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma. Bone Marrow Transplant 2009; 43:237-244.
24. Meijer E, Dekker AW, Lokhorst HM, et al. Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation. Transpl Infect Dis 2004; 6:171-178. (Pubitemid 40516685)
25. Van Besien K, Dew A, Lin S, et al. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma 2009; 50:1809-1817.
26. Mattsson J, Uzunel M, Remberger M, Ringden O. T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 2001; 71:433-439. (Pubitemid 32175982)
27. Couriel DR, Saliba RM, Giralt S, et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004; 10:178-185. (Pubitemid 38262880)
28. Perez-Simon JA, Diez-Campelo M, Martino R, et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graftversus- host disease after allogeneic transplantation. Br J Haematol 2005; 130:394-403. (Pubitemid 43899588)